Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Finished Goods: 2017-2023

Historic Finished Goods for China Pharma Holdings (CPHI) over the last 7 years, with Dec 2023 value amounting to $1.5 million.

  • China Pharma Holdings' Finished Goods rose 6.83% to $1.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.3 million, marking a year-over-year increase of 6.83%. This contributed to the annual value of $1.5 million for FY2023, which is 166.73% up from last year.
  • As of FY2023, China Pharma Holdings' Finished Goods stood at $1.5 million, which was up 166.73% from $551,000 recorded in FY2022.
  • China Pharma Holdings' Finished Goods' 5-year high stood at $1.5 million during FY2023, with a 5-year trough of $551,000 in FY2021.
  • Moreover, its 3-year median value for Finished Goods was $551,000 (2022), whereas its average is $857,236.
  • Per our database at Business Quant, China Pharma Holdings' Finished Goods plummeted by 42.63% in 2021 and then spiked by 166.73% in 2023.
  • China Pharma Holdings' Finished Goods (Yearly) stood at $1.2 million in 2019, then decreased by 17.25% to $960,375 in 2020, then crashed by 42.63% to $551,000 in 2021, then remained steady at $551,000 in 2022, then spiked by 166.73% to $1.5 million in 2023.